Clinical Trials Logo

Clinical Trial Summary

To tested if the adding of consolidative SBRT to TKI in EGFR mutated patients with less than or equal to 5 metastatic sites (primary + 5) will improve progression free survival (PFS) compared to TKI alone.


Clinical Trial Description

This protocol is a randomized phase III trial of TKI versus consolidative Stereotactic Body Radiation Therapy (SBRT) plus TKI for patients with Stage IV non-small cell lung cancer (NSCLC).

Prior to accrual on the trial, patients with Stage IV NSCLC will be treated with positive EGFR mutation. Patients who with fewer than or equal to 5 sites of oligometastatic disease will be randomized toTKI or consolidative SBRT to all sites of disease (followed by TKI at the medical oncologist's discretion). Choices of TKI will be determined by the medical oncologist based on clinical appropriateness. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02893332
Study type Interventional
Source Sichuan Provincial People's Hospital
Contact Ming Zeng, MD PhD
Phone 00861708131336
Email miller2002@yahoo.acom
Status Recruiting
Phase Phase 3
Start date March 2016
Completion date December 2020